Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT03209973Phase 2Completed
- Sponsor
- BeiGene
- Start
- Apr 2017
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in classical Hodgkin lymphoma (cHL), sponsored by BeiGene. Primary endpoint: Overall Response Rate. Started Apr 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03209973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03209973.